Abstract -Endocannabinoids and CB 1 receptors (CB 1 ) have been implicated in endotoxin (lipopolysaccharide [LPS])-induced hypotension: LPS stimulates the synthesis of anandamide in macrophages, and the CB 1 antagonist SR141716 inhibits the hypotension induced by treatment of rats with LPS or LPS-treated macrophages. Recent evidence indicates the existence of cannabinoid receptors distinct from CB 1 or CB 2 which are inhibited by SR141716 but not by other CB 1 antagonists such as AM251. In pentobarbital-anesthetized rats, i.v. injection of 10 mg/kg LPS elicits hypotension associated with profound decreases in cardiac contractility, moderate tachycardia and an increase in lower body vascular resistance. Pretreatment with 3 mg/kg SR141716 prevented the hypotension and decrease in cardiac contractility, slightly attenuated the increase in peripheral resistance and had no effect on the tachycardia caused by LPS, whereas pretreatment with 3 mg/kg AM251 did not affect any of these responses.
ACTIVATION OF CANNABINOID RECEPTORS by plant-derived and endogenous
cannabinoids elicits well documented cardiovascular effects (17, 25) . In humans, acute ingestion of ∆ 9 -tetrahydrocannabinol (THC), the main psychoactive ingredient of marijuana, usually elicits tachycardia (24) . However, prolonged use in humans and acute as well as chronic administration in most animal models causes long lasting hypotension and bradycardia (4, 26) , and similar depressor effects have been also reported in response to the acute administration of the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) (22, 45) . The introduction in 1994 of the first selective cannabinoid-1 receptor (CB 1 ) antagonist, SR141716 (40) , has allowed these responses to be characterized as CB 1 -mediated (45), a conclusion later borne out by the absence of cannabinoid-induced hypotension and bradycardia in mice with genetic ablation of CB 1 (23, 27) . Although the overwhelming majority of CB 1 in mammals are located in the brain (16) , the cardiovascular depressor effects of cannabinoids appear to involve CB 1 expressed in peripheral tissues, including blood vessels (13, 17, 29) , the heart (5), and sympathetic nerve terminals (20, 30) . The possible involvement in cardiovascular depressor responses of CB 2 (15) , another cannabinoid receptor primarily expressed by immune cells (33) , is less well documented.
Activation of CB 1 by certain synthetic cannabinoids can cause profound and prolonged hypotension (26) , which has raised the possible involvement of the CB 1 /endocannabinoid system in pathological states associated with hypotension, such as various forms of shock. Indeed, the CB 1 antagonist SR141716 has been reported to inhibit or reverse the hypotension associated with hemorrhagic (48), endotoxemic (46) , and cardiogenic shock (47) and the hypotension that accompanies advanced liver cirrhosis (2, 41) . There is also evidence that in these conditions, macrophage-and platelet-derived endocannabinoids, including anandamide and 2-arachidonoylglycerol (2-AG) are responsible for the activation of SR141716-sensitive receptors (2, 41, (46) (47) (48) 50 In anesthetized rats, the acute (< 2h) hypotensive phase following LPS injection is primarily due to a decrease in cardiac contractility, and both the hypotension and the decreased contractility are prevented by SR141716 but are unaffected by another CB 1 antagonist, AM251 (12) . 
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We have previously reported that the CB1 antagonist SR141716 inhibits the acute hypotension and decreases mortality in response to LPS treatment in rats (46) . The present findings confirm the ability of SR141716 to inhibit LPS-induced hypotension, yet indicate that this effect and the underlying hemodynamic changes are not mediated by CB 1 . AM251 is a selective CB 1 antagonist at least equipotent with SR141716 (12) , and at the in vivo dose used here it was reported to block the hemodynamic effects of potent CB 1 agonists in rats (11). Thus, its complete inability to influence the LPS response ( Fig.   3 ) is not compatible with CB 1 involvement. Furthermore, LPS-induced hypotension in mice and its sensitivity to inhibition by SR141716 were not influenced by the genetic ablation of CB 1 or both CB 1 and CB 2 (Fig. 4) .
Several recent studies point to the existence of additional cannabinoid receptors distinct from CB 1 or CB 2 . At least two of these, a putative G i /G o -coupled endothelial receptor mediating vasodilation in certain vascular beds (18, 23, 32, 34) , and a receptor postulated to be present on glutamatergic terminals in the hippocampus (14) , have been shown to be uniquely sensitive to inhibition by SR141716 but not by other CB 1 antagonists such as AM251, although their differential sensitivity to the agonist WIN55,212-2 (14, 32, 34) suggests that they are distinct molecular entities. LPS is a potent stimulant of anandamide synthesis in macrophages (28, 46) , and LPS-treated macrophages were found to elicit SR141716-sensitive hypotension when injected into normal control rats (28, 46) . Since anandamide can interact with SR141716-sensitive non-CB 1 /non-CB 2 receptors described above (23, 32, 34) , one might postulate that such a receptor rather than CB 1 may mediate the acute hemodynamic effects of LPS.
Macrophages isolated from mice deficient in fatty acid amidohydrolase, the enzyme responsible for anandamide metabolism, and stimulated in vitro with LPS have higher anandamide levels and elicit a greater decrease in blood pressure in recipient rats than similarly treated cells isolated from wild-type littermates (28) . Although these findings suggest that macrophage-derived anandamide or a related fatty acid amide may mediate the acute hemodynamic effect of LPS, other mechanisms, such as a reported LPS-induced increase in target organ sensitivity to endocannabinoids (35) may also play a role.
The present findings also indicate, however, that the hypotensive effect of LPS is due to decreased cardiac contractility, which leads to a decrease in stroke volume and cardiac output, rather than vasodilation, and the decrease in contractility is so profound that arterial pressure decreases despite a parallel increase in peripheral resistance. This hemodynamic pattern of a primary decrease in cardiac contractility is similar to that reported in several recent studies in both anesthetized (19, 31, 36, 39) and conscious rats (42) , although an LPS-induced vasodilation in certain vascular beds, such as the renal vasculature (11), the heart and the brain (44) would not be detected in the present experiments due to the positioning of the aortic flow probe. The primary cardiodepressor effect of LPS suggests that SR141716 must have a myocardial site of action as well.
Indeed, SR141716 not only prevents the marked decrease in dP/dt and LVSP of subsequently administered LPS, but elicits an immediate reversal of the decline in these parameters to levels above control values when it is administered once the hemodynamic response to LPS has fully developed. Similarly, cardiac contractility increased above control values when LPS was administered after pretreatment with SR141716 (Fig. 1) .
This is an interesting phenomenon in which increased sympathetic nervous system drive may play a role: LPS has been reported to increase sympathetic tone in rats, as indicated by a rise in plasma catecholamines (21) . Thus, the net effect of LPS on cardiac contractility may be determined by the balance between endocannabinoid-mediated negative and sympathetically mediated positive inotropy, although the involvement of additional mechanisms cannot be excluded.
In contrast, SR141716 only slightly delays but does not significantly inhibit the LPS-induced decrease in aortic blood flow and increase in peripheral resistance.
Although these findings do not exclude the possibility that SR141716 may antagonize LPS-induced vasodilation in vascular beds where they do occur, it appears that the primary site of action of SR141716 in this experimental model is cardiac, not vascular.
An SR141716-sensitive, AM251-insensitive negative inotropic response to anandamide has been described in the rat Langendorff heart preparation (8) 
